The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Head-to-Head Comparison of the Activities of Currently Available Antifungal Agents against 3,378 Spanish Clinical Isolates of Yeasts and Filamentous Fungi
Open accessAbstract
We have compared the activities of posaconazole and other currently available antifungal agents against a collection of 3,378 clinical isolates of yeasts and filamentous fungi. A total of 1,997 clinical isolates of Candida spp., 359 of other yeast species, 697 strains of Aspergillus spp., and 325 nondermatophyte non- Aspergillus spp. were included. The average geometric means of the MICs of agents that were tested against Candida spp. were 0.23 μg/ml for amphotericin B, 0.29 μg/ml for flucytosine, 0.97 μg/ml for fluconazole, 0.07 μg/ml for itraconazole, 0.04 μg/ml for voriconazole, 0.15 μg/ml for caspofungin, and 0.03 μg/ml for posaconazole. Voriconazole and posaconazole were active in vitro against the majority of isolates, with resistance to fluconazole and itraconazole, and against Cryptococcus neoformans and other Basidiomycota yeasts. Posaconazole was the most active of antifungal agents tested against Aspergillus spp., with an average geometric mean of 0.10 μg/ml. It was active against Paecilomyces spp., Penicillium spp., Scedosporium apiospermum , and some black fungi, such as Alternaria spp. Multiresistant filamentous fungi, such as Scedosporium prolificans , Scopulariopsis brevicaulis , and Fusarium solani , were also resistant to voriconazole, caspofungin, and posaconazole. Amphotericin B and posaconazole were found to be active against most of the Mucorales strains tested. Posaconazole and currently available antifungal agents exhibit a potent activity in vitro against the majority of pathogenic fungal species.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It appears that variations in the structure of azoles are responsible for the cross-resistance patterns among Candida species [92–94].”
From Candida Infections, Causes, Targets, and Resistance Mechanisms: Traditional and Alternative Antifungal Agents (2013) · cites this paper as [92]
Experimental — accuracy not yet measuredIn the citing paper
“Despite the variation in incidence found among the different population-based studies, the rate of IC is far higher than that of any other invasive mycosis (Tables 2 and 4) and is comparable to those of many invasive bacterial diseases (52, 74, 125, 193).”
From Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem (2007) · cites this paper as [52]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · PEDIATRICS · doi:10.1542/peds.65.1.187 · Cited by 14,736
Pfaller, M. A., Messer, S. A., Hollis, R. J., & Jones, R. N. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.4.1032-1037.2002 · Cited by 405
Diekema, D. J., Messer, S. A., Hollis, R. J., Jones, R. N., & Pfaller, M. A. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.8.3623-3626.2003 · Cited by 370
Courtney, R., Wexler, D. B., Radwanski, E., Lim, J. M., & Laughlin, M. A. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01977.x · Cited by 328
In vitro susceptibilities of zygomycetes to conventional and new antifungals
Dannaoui, É. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg020 · Cited by 312
Walsh, T. J., Petraitis, V., Petraitienė, R., Field‐Ridley, A., Sutton, D. A., Ghannoum, M. A., Sein, T., Schaufele, R. L., Peter, J., Bacher, J. D., et al. (2003) · The Journal of Infectious Diseases · doi:10.1086/377210 · Cited by 252
(2003) · PubMed · Cited by 240
Denning, D. W. (1997) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/40.3.401 · Cited by 234
In Vitro Activities of New and Conventional Antifungal Agents against ClinicalScedosporiumIsolates
Meletiadis, J., Meis, J. F. G. M., Mouton, J. W., Rodriquez-Tudela, J. L., Donnelly, J. P., Verweij, P. E., & the EUROFUNG Network (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.1.62-68.2002 · Cited by 232
Cuenca‐Estrella, M., Ruiz-Dı́ez, B., Martı́nez-Suárez, J. V., Monzón, A., & Rodrı́guez-Tudela, J. L. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/43.1.149 · Cited by 211
Self-citationRodríguez-Tudela, J. L., Barchiesi, F., Billé, J., Chryssanthou, E., Cuenca‐Estrella, M., Denning, D. W., Donnelly, J. P., Dupont, B., Fegeler, W., Moore, C. B., et al. (2003) · Clinical Microbiology and Infection · doi:10.1046/j.1469-0691.2003.00789.x · Cited by 208
Self-citationOral Bioavailability of Posaconazole in Fasted Healthy Subjects
Ezzet, F., Wexler, D. B., Courtney, R., Krishna, G., Lim, J. M., & Laughlin, M. A. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544020-00006 · Cited by 208
In Vivo Activity of Posaconazole againstMucorspp. in an Immunosuppressed-Mouse Model
Sun, Q. N., Najvar, L. K., Bocanegra, R. A., Loebenberg, D., & Graybill, J. R. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.7.2310-2312.2002 · Cited by 184
In Vitro Antifungal Susceptibilities of Trichosporon Species
Paphitou, N. I., Ostrosky‐Zeichner, L., Paetznick, V. L., Rodriguez, J. R., Chen, E., & Rex, J. H. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.4.1144-1146.2002 · Cited by 176
Odds, F. C., Motyl, M. R., Andrade, R. A., Billé, J., Cantón, E., Cuenca‐Estrella, M., Davidson, A. D., Durussel, C., Ellis, D., Foraker, E., et al. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.8.3475-3482.2004 · Cited by 173
Self-citationKeating, G. M. (2005) · Drugs · doi:10.2165/00003495-200565110-00007 · Cited by 158
Cuenca‐Estrella, M., Moore, C. B., Barchiesi, F., Billé, J., Chryssanthou, E., Denning, D. W., Donnelly, J. P., Dromer, F., Dupont, B., Rex, J. H., et al. (2003) · Clinical Microbiology and Infection · doi:10.1046/j.1469-0691.2003.00592.x · Cited by 157
Self-citationPfaller, M. A., Messer, S. A., Hollis, R. J., & Jones, R. N. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2862-2864.2001 · Cited by 144
Posaconazole: clinical pharmacology and potential for management of fungal infections
Groll, A. H., & Walsh, T. J. (2005) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.3.4.467 · Cited by 114
Cacciapuoti, A. F., Loebenberg, D., Corcoran, E., Menzel, F., Moss, E. L., Norris, C., Michalski, M., Raynor, K., Halpern, J., Mendrick, C. A., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.8.2017-2022.2000 · Cited by 110
González, G. M., Fothergill, A. W., Sutton, D. A., Rinaldi, M. G., & Loebenberg, D. (2005) · Medical Mycology · doi:10.1080/13693780500088416 · Cited by 103
Scopulariopsis brevicaulis, a Fungal Pathogen Resistant to Broad-Spectrum Antifungal Agents
Cuenca‐Estrella, M., Gómez‐López, A., Mellado, E., Buitrago, M. J., Monzón, A., & Rodrı́guez-Tudela, J. L. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.7.2339-2341.2003 · Cited by 99
Self-citationBarchiesi, F., Arzeni, D., Fothergill, A. W., Francesco, L. F. D., Caselli, F., Rinaldi, M. G., & Scalise, G. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.1.226-229.2000 · Cited by 80
Gupta, A. K., Kohli, Y., & Batra, R. (2004) · Medical Mycology · doi:10.1080/13693780410001731583 · Cited by 79
Rodriguez-Tudela, J. L., Chryssanthou, E., Petrikkou, E., Mosquera, J., Denning, D. W., & Cuenca-Estrella, M. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.11.5236-5237.2003 · Cited by 79
Self-citationLaverdière, M. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkf074 · Cited by 73
In vitro antifungal activity of posaconazole against various pathogenic fungi
Uchida, K., Yokota, N., & Yamaguchi, H. (2001) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(01)00363-6 · Cited by 68
Gomez-Lopez, A., Aberkane, A., Petrikkou, E., Mellado, E., Rodriguez-Tudela, J. L., & Cuenca-Estrella, M. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.3.1251-1255.2005 · Cited by 53
Self-citationSafdar, A. (2002) · Clinical Infectious Diseases · doi:10.1086/340260 · Cited by 48
Rodrı́guez-Tudela, J. L., Martín-Díez, F., Cuenca‐Estrella, M., Rodero, L., Carpintero, Y., & Gorgojo, B. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.2.400-404.2000 · Cited by 41
Self-citationCarrillo-Muñoz, A.-J., Quindós, G., Ruesga, M., Alonso, R., del Valle, O., Hernández-Molina, J. M., McNicholas, P. M., Loebenberg, D., & Santos, P. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki022 · Cited by 31
Research works printed but not linked: 1
- Keating, G. M. 2006. Posaconazole. Drugs65:1553-1567.
Cited by
Sorted by citations
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174
Fusarium Infections in Immunocompromised Patients
Nucci, M., & Anaissie, E. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00014-07 · Cited by 979
Epidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901
Resistance to Antifungal Agents: Mechanisms and Clinical Impact
Kanafani, Z. A., & Perfect, J. R. (2008) · Clinical Infectious Diseases · doi:10.1086/524071 · Cited by 619
Melanized Fungi in Human Disease
Revankar, S. G., & Sutton, D. A. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00019-10 · Cited by 577
Metadata
- Authors
- Cuenca-Estrella, M., Gomez-Lopez, A., Mellado, E., Buitrago, M. J., Monzon, A., & Rodriguez-Tudela, J. L.
- Affiliations
- Servicio de Micología, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain
- Instituto de Salud Carlos III (ES)
- ORCID
- Mellado, Emilia
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2006-03
- Volume
- 50
- Issue
- 3
- Pages
- 917-921
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC1426453
- OpenAlex
- W2160917189
- Cited by
- 298
- References
- 32
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 6 · 2023: 6 · 2022: 5 · 2021: 9 · 2020: 11 · 2019: 3 · 2018: 8 · 2017: 10 · 2016: 12 · 2015: 10 · 2014: 20 · 2013: 14 · 2012: 9
- FWCI
- 23.42
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- posaconazole, antifungal agents, clinical fungal isolates, Candida, Aspergillus, filamentous fungi, antifungal susceptibility, minimum inhibitory concentration, voriconazole resistance, caspofungin, amphotericin B, fluconazole resistance, itraconazole, Cryptococcus neoformans, Scedosporium prolificans, Scedosporium apiospermum, Paecilomyces, Penicillium, Mucorales, black fungus, Spanish isolates
- MeSH terms
- Caspofungin, Amphotericin B, Antifungal Agents, Flucytosine, Fungi, Humans, Microbial Sensitivity Tests, Mycoses, Peptides, Cyclic, Pyrimidines, Spain, Triazoles, Yeasts, Fluconazole, Itraconazole, Echinocandins, Lipopeptides, Voriconazole
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
